ESR1 and breast carcinoma: In breast cancer, AHR activation reduces the proliferation of estrogen receptor-positive breast cancer cells, while both AHR agonists and antagonists have been reported to reduce colony formation, migration and metastasis of triple negative breast cancer cell lines (14, 15).